Brand VerifiedUnited States

Elanco Animal Health Incorporated

Elanco

Elanco Animal Health is a top-tier global animal health company that has undergone a dramatic strategic transformation since its 2018 spin-off from Eli Lilly. Headquartered in Greenfield, Indiana, USA, the company generated USD 4.715 billion in 2025 revenue (up 6% reported, 7% organic), employing 9,300 employees across 17 manufacturing sites. Elanco is in the midst of a historic innovation renaissance—all six of its promised "Big 6" potential blockbuster drugs have been successfully delivered to market, including the JAK inhibitor Zenrelia (penetrating 50% of US clinics) and IL-31 mAb Befrena, which together generated $8.92 billion in 2025 innovation revenue.

Strengths:
• Innovation Pipeline Execution: All six "Big 6" blockbuster candidates successfully commercialized, including Zenrelia (JAK inhibitor) achieving 50% US clinic penetration within months
• Companion Animal Focus: Pet Health segment contributing $23B—nearly half of total revenue—driven by dermatology, parasiticide, and OA pain franchises
• Strategic Portfolio Rationalization: Sale of aquaculture business to Merck for $1.29B and divestiture of three underperforming manufacturing sites are sharpening operational focus
• Restructuring Discipline: "Elanco Ascend" program targeting $200-250M in annual EBITDA savings by 2030 through facility optimization and SG&A streamlining
• Global Diversification: Operations spanning 90+ countries with manufacturing facilities across four continents providing regional supply chain resilience
Weaknesses:
• Profitability Headwinds: Reported net loss of $2.32B in 2025 due to $1.75B in restructuring charges and significant intangible asset amortization from historical acquisitions
• Elevated Leverage: Net debt-to-adjusted EBITDA ratio of 3.6x, requiring disciplined deleveraging to regain full financial flexibility
• Manufacturing Transition Risk: Simultaneous divestiture of three facilities (Brazil, Kansas, UK) while launching six new products creates complex supply chain coordination challenges

Business Nature

Elanco Animal Health, spun off from Eli Lilly in 2018, operates a hybrid manufacturing model combining heavy in-house production with strategic CDMO partnerships. The company maintains 17 core manufacturing sites across four continents, covering biologics fermentation UK Speke legacy capacity, oral solid dosage France Huningue, API and formulation synthesis China Wuxi, and advanced vaccine R&D/manufacturing Canada PEI and Germany Cuxhaven.

Under the "Elanco Ascend" productivity initiative targeting $200-250 million in EBITDA savings by 2030, the company is strategically streamlining: exiting three underutilized facilities (Brazil Belford Roxo closed; Kansas Shawnee and UK Speke sold to CDMO TriRx with long-term supply agreements), while concentrating investment in its Indianapolis OneHealth Innovation Lab and expanding US-based manufacturing to mitigate tariff risks and accelerate FDA/USDA approvals.

Core Business Areas

Companion Animal Portfolio — Core Business
• Dermatology: Zenrelia JAK inhibitor / Befrena IL-31 mAb
• Parasiticides: Credelio / Interceptor Plus
• Pain & Osteoarthritis: Galliprant
• Vaccines and specialty therapeutics
• Livestock and poultry health products

Industry Rankings

4Top 10 Veterinary Pharmaceuticals & Pet Healthcare Companies

Brand

4Top 10 Veterinary Pharmaceuticals & Pet Healthcare Manufacturers & Suppliers

Mfr

Corporate Report

Elanco Animal Health is a United States-based global animal health company headquartered in Greenfield, Indiana. Originally founded in 1954 as Eli Lilly's animal health division and spun off as an independent public company in 2018. In 2025, Elanco generated USD 4.715 billion in global revenue, employing 9,300 people across 17 manufacturing sites and 90+ countries of operation.

Core Business

Elanco's transformation is anchored by the successful commercialization of its "Big 6" innovation pipeline—a portfolio of potential blockbuster drugs spanning dermatology, parasitology, and pain management. Zenrelia (JAK inhibitor for canine atopic dermatitis) achieved 50% US clinic penetration within months of launch, while Befrena (IL-31 mAb) represents the next generation of targeted dermatology biologics. Galliprant remains the leading NSAID for canine osteoarthritis, and the Credelio parasiticide family provides broad-spectrum protection.

Global Presence

Elanco's 17 manufacturing sites span the US, Canada, UK, France, Germany, China, and Brazil, covering the full pharmaceutical production spectrum from API synthesis to finished dose manufacturing. Under the "Elanco Ascend" restructuring program, the company is divesting three underutilized facilities while concentrating investment in US-based manufacturing and the Indianapolis OneHealth Innovation Lab. The 2024 sale of the aquaculture business to Merck for $1.29B further sharpened the strategic focus on companion animal and livestock core markets.

Key Strengths

• Successful "Big 6" innovation pipeline delivery with $8.92B in 2025 innovation product revenue
• Balanced portfolio with $23B companion animal and $23.62B livestock revenue
• Aggressive restructuring targeting $200-250M in annual EBITDA savings by 2030
• Zenrelia achieving remarkable 50% US veterinary clinic penetration in launch year
• Global manufacturing presence across four continents with targeted capacity optimization

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Greenfield, Indiana, USA

Founded

1954

Employees

9,300

Factories

17 manufacturing sites globally

Listing

NYSE: ELAN

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE: ELAN , Elanco Official Website
SEC EDGAR — Elanco Filings
Wikipedia — Elanco

Back to Rankings